Epstein–Barr virus latent membrane protein 1 increases genomic instability through Egr-1-mediated up-regulation of activation-induced cytidine deaminase in B-cell lymphoma

References

• Fåhraeus R, Fu HL, Ernberg I, et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 1988;42:329–338.
   PubMed Web of Science ®Google Scholar
• Weiss LM, Movahed LA, Warnke RA, et al. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 1989;320:502–506.
   PubMed Web of Science ®Google Scholar
• Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol 1992;140:769–774.
   PubMed Web of Science ®Google Scholar
• Kwon JM, Park YH, Kang JH, et al. The effect of Epstein-Barr virus status on clinical outcome in Hodgkin's lymphoma. Ann Hematol 2006;85:463–468.
   PubMed Web of Science ®Google Scholar
• Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007; 110:972–978.
   PubMed Web of Science ®Google Scholar
• Murray PG, Young LS, Rowe M, et al. Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein in paraffin sections of Hodgkin's disease. J Pathol 1992;166:1–5.
   PubMed Web of Science ®Google Scholar
• Peng M, Lundgren E. Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 1992;7:1775–1782.
   PubMed Web of Science ®Google Scholar
• Huen DS, Henderson SA, Croom-Carter D, et al. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995;10:549–560.
   PubMed Web of Science ®Google Scholar
• Gires O, Zimber-Strobl U, Gonnella R, et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J 1997;16:6131–6140.
   PubMed Web of Science ®Google Scholar
• Mcfarland EDC, Izumi KM, Mosialos G. Epstein-Barr virus transformation involvement of latent membrane protein 1-mediated activation of NFkB. Oncogene 1999;19:6959–6964.
   Web of Science ®Google Scholar
• Baumforth KR, Young LS, Flavell KJ, et al. The Epstein-Barr virus and its association with human cancers. Mol Pathol 1999;52:307–322.
   PubMedGoogle Scholar
• Kim JH, Kim WS, Kang JH, et al. Egr-1, a new downstream molecule of Epstein-Barr virus latent membrane protein 1. FEBS Lett 2007;581:623–628.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim WS, Park C. SNARK, a novel downstream molecule of EBV latent membrane protein 1, is associated with resistance to cancer cell death. Leuk Lymphoma 2008;49:1392–1398.
   PubMed Web of Science ®Google Scholar
• He B, Raab-Traub N, Casali P, et al. EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol 2003;171: 5215–5224.
   PubMed Web of Science ®Google Scholar
• de Yébenes VG, Ramiro AR. Activation-induced deaminase:light and dark sides. Trends Mol Med 2006;12:432–439.
   PubMed Web of Science ®Google Scholar
• Longerich S, Basu U, Alt F, Storb U. AID in somatic hypermutation and class switch recombination. Curr Opin Immunol 2006;18: 164–174.
   Google Scholar
• Delker RK, Fugmann SD, Papavasiliou FN. A coming-of-age story: activation-induced cytidine deaminase turns 10. Nat Immunol 2009;10:1147–1153.
   Google Scholar
• Kuraoka M, McWilliams L, Kelsoe G. AID expression during B-cell development: searching for answers. Immunol Res 2011;49:3–13.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001;412:341–346.
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Lonetti A, Messa F, et al. Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients. Leukemia 2010;24:66–73.
   PubMed Web of Science ®Google Scholar
• Nagaoka H, Tran TH, Kobayashi M, et al. Preventing AID, a physiological mutator, from deleterious activation:regulation of the genomic instability that is associated with antibody diversity. Int Immunol 2010;22:227–235.
   PubMed Web of Science ®Google Scholar
• Park SR, Zan H, Pal Z, et al. HoxC4 binds to the promoter of the cytidine deaminase AID gene to induce AID expression, class-switch DNA recombination and somatic hypermutation. Nat Immunol 2009; 10:540–550.
   PubMed Web of Science ®Google Scholar
• Allen NP, Donninger H, Vos MD, et al. RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene 2007;26: 6203–6211.
   PubMed Web of Science ®Google Scholar
• Epeldegui M, Hung YP, McQuay A, et al. Infection of human B cells with Epstein-Barr virus results in the expression of somatic hypermutation-inducing molecules and in the accrual of oncogene mutations. Mol Immunol 2007;44:934–942.
   PubMed Web of Science ®Google Scholar
• Gonda H, Sugai M, Nambu Y, et al. The balance between Pax5 and Id2 activities is the key to AID gene expression. J Exp Med 2003;198:1427–1437.
   PubMed Web of Science ®Google Scholar
• Dedeoglu F, Horwitz B, Chaudhuri J, et al. Induction of activation-induced cytidine deaminase gene expression by IL-4 and CD40 ligation is dependent on STAT6 and NFkappaB. Int Immunol 2004;16: 395–404.
   PubMed Web of Science ®Google Scholar
• Yadav A, Olaru A, Saltis M, et al. Identification of a ubiquitously active promoter of the murine activation-induced cytidine deaminase (AICDA) gene. Mol Immunol 2006;43:529–541.
   PubMed Web of Science ®Google Scholar
• Ikeda M, Hirabayashi S, Fujiwara N, et al. Ras-association domain family protein 6 induces apoptosis via both caspase-dependent and caspase-independent pathways. Exp Cell Res 2007;313:1484–1495.
   PubMed Web of Science ®Google Scholar
• Hasham MG, Donghia NM, Coffey E, et al. Widespread genomic breaks generated by activation-induced cytidine deaminase are prevented by homologous recombination. Nat Immunol 2010;11:820–826.
   Google Scholar
• Matsumoto Y, Marusawa H, Kinoshita K, et al. Up-regulation of activation-induced cytidine deaminase causes genetic aberrations at the CDKN2b-CDKN2a in gastric cancer. Gastroenterology 2010;139:1984–1994.
   PubMed Web of Science ®Google Scholar
• Robbiani DF, Bunting S, Feldhahn N, et al. AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations. Mol Cell 2009;36: 631–641.
   PubMed Web of Science ®Google Scholar
• Lawler J, Detmar M. Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 2004;36:1038–1045.
   PubMed Web of Science ®Google Scholar
• Chiliwa T, Abe Y, Ikoma N, et al. Thromobospondin 2 inhibits metastasis of human malignant melanoma through microenvironment modification in NOD/SCID/gamaCnull (NOG) mice. Int J Oncol 2009; 34:5–13.
   PubMed Web of Science ®Google Scholar
• Fütterer A, Campanero MR, Leonardo E, et al. Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms. J Clin Invest 2005;115:2351–2362.
   PubMed Web of Science ®Google Scholar
• García-Domingo D, Leonardo E, Grandien A, et al. DIO-1 is a gene involved in onset of apoptosis in vitro, whose misexpression disrupts limb development. Proc Natl Acad Sci USA 1999;96:7992–7997.
   PubMed Web of Science ®Google Scholar
• Wu H, Ma Y, Zhu Y, et al. Expression of BIRC7 protein and mRNA in non-Hodgkin's lymphoma. Leuk Lymphoma 2006;47:1110–1116.
   PubMed Web of Science ®Google Scholar
• Smolewski P, Robak T. Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies. Curr Mol Med 2011;11:633–649.
   PubMed Web of Science ®Google Scholar
• Ohshima K, Haraoka S, Sugihara M, et al. Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas. Cancer Lett 2000;160:89–97.
   PubMed Web of Science ®Google Scholar
• Ho CH, Hsu CF, Fong PF, et al. Epstein-Barr virus transcription activator Rta upregulates decoy receptor 3 expression by binding to its promoter. Virology 2007;81:4837–4847.
   Web of Science ®Google Scholar
• Chang PM, Chen PM, Hsieh SL, et al. Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome. Int J Oncol 2008;33:549–554.
   PubMed Web of Science ®Google Scholar